The latest development in the minimally invasive glaucoma surgical (MIGS) space comes from Glaukos (Laguna Hills, California) as the company has reportedly filed for an initial public offering (IPO) to raise $86 million.

Medtronic's (Dublin), Arctic Front Advance ST Cryoablation Catheter, which uses coolant rather than heat for patients suffering from atrial fibrillation, is warming up the market, as the device has reportedly gained FDA approval and CE mark approval. The company noted that the two approvals deal with separate indications and said that the PMA approval would allow for the treatment of patients with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.

In 1Q15, many med-tech companies avoided acquiring firms that had huge regulatory burdens to overcome, and instead picked up companies with products that could be used outside of the hospital setting, according to a new report released from The Walden Group (Tarrytown, New York).

There has been quite a bit of significant developments in the minimally invasive glaucoma surgeries (MIGS) space recently. The most recent one came this week from Transcend Medical (Menlo Park, California), a privately held firm that has developed the CyPass Micro-Stent, a minimally invasive glaucoma surgical (MIGS) implant.

Biotronik (Lake Oswego, Oregon) is hoping that the addition of its established Closed Loop Stimulation (CLS) sensor in the latest generation of its Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices will give it a leg up on the competition in the global cardiac pacemakers sector, which is projected to reach $5.7 billion by next year, according to Research and Markets.